Compare FMC Corp (FMC) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Humana Inc — how do they compare? FMC Corp trades at $11.4 (market cap $1.36B), while Humana Inc trades at $386.89 (market cap $48.96B). The key difference: Humana Inc is far larger — about 36× FMC Corp's market cap, and FMC Corp pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| FMC | HUM | |
|---|---|---|
Market Cap | $1.36B | $48.96B |
Sector | Basic Materials | Health |
52-Week High | $43.90 | $409.42 |
52-Week Low | $10.72 | $163.67 |
Enterprise Value | $5.50B | $58.00B |
Dividend Yield | 2.95% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.
The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.
Humana (HUM) trades at $395.78, down 2.68% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $10.31, beating expectations, and maintains a P/E of 43.52 and P/S of 0.36. Recent news highlights margin recovery targets and expansion through CenterWell, while investigations into insider sales and cost statements introduce uncertainty.
Outlook is mixed: analyst consensus is $354.33 with 61% hold ratings, reflecting caution despite growth initiatives. Key risks include Medicare Advantage margin pressures and legal scrutiny, but revenue growth to $137.2B in 2026 and a dividend payment in July offer support. Investors should weigh profitability trends against valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
